Gilotrif Improves PFS Compared to Iressa in Phase IIb Trial in Non-Small Cell Lung Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results of the LUX-Lung 7 trial met two of its co-primary endpoints, in progression-free survival and time to treatment failure, with EGFR-directed therapy Gilotrif (afatinib) compared to Iressa (gefitinib) in the first-line treatment of patients with advanced non-small cell lung cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more

Login